OOIR: Observatory of International Research

Papers

(The H4-Index of Alzheimers Research & Therapy is 49. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2022-08-01 to 2026-08-01.)

Article	Citations
A novel electric field approach for improving cognitive function through ameliorating cell-specific pathology in P301S tauopathy mice	261
A biomarker-validated time scale in years of disease progression has identified early- and late-onset subgroups in sporadic Alzheimer’s disease	257
Associations of adherence to a healthy sleep pattern with the dementia risk in the UK biobank	189
Recent molecular insights and biosensor-based diagnostic technologies for hyperphosphorylated Tau in Alzheimer's disease	179
Correction: 18F-FDG PET can effectively rule out conversion to dementia and the presence of CSF biomarker of neurodegeneration: a real-world data analysis	172
Longitudinal evaluation of common and unique brain-networks in variants of primary progressive aphasia	166
Development of a Japanese polygenic risk score model for amyloid-β PET imaging in Alzheimer’s disease	156
Anti-tau VHH therapy against PHF6: a safe approach to slowing the phenotype of tau pathology	138
Linking eye movements, pupil responses, and brain networks in early cognitive decline	133
Comparing a pre-defined versus deep learning approach for extracting brain atrophy patterns to predict cognitive decline due to Alzheimer’s disease in patients with mild cognitive symptoms	131
Impact of gender on the willingness to participate in clinical trials and undergo related procedures in individuals from an Alzheimer’s prevention research cohort	128
An association of CSF apolipoprotein E glycosylation and amyloid-beta 42 in individuals who carry the APOE4 allele	126
Moderating role of executive function in the relationship between specific white matter changes and long-term delayed recall in aMCI patients	115
Prominent tauopathy and intracellular β-amyloid accumulation triggered by genetic deletion of cathepsin D: implications for Alzheimer disease pathogenesis	110
Diagnostic performance of verbal fluency measures: a cross-sectional study in the stages of cognitive continuum	109
Serum phosphorylated tau protein 181 and neurofilament light chain in cognitively impaired heart failure patients	109
Structural brain improvements following individually tailored serious exergame-based training in mild neurocognitive disorders: exploratory randomized controlled trial	101
Association of modifiable risk factors with progression to dementia in relation to amyloid and tau pathology	100
Serum and cerebrospinal fluid neurofilament light chain and glial fibrillary acid protein levels in early and advanced stages of cerebral amyloid Angiopathy	98
Greater baseline cortical atrophy in the dorsal attention network predicts faster clinical decline in Posterior Cortical Atrophy	95
A multicenter, randomized, double-blind, placebo-controlled ascending dose study to evaluate the safety, tolerability, pharmacokinetics (PK) and pharmacodynamic (PD) effects of Posiphen in subjects wi	95
Global and domain-specific cognitive intraindividual variability associations with neurodegenerative diagnoses and postmortem pathologies	90
Stress-induced alteration of small extracellular vesicles drives amyloid-beta sequestration and exacerbates Alzheimer’s disease pathogenesis	85
Amyloid-β PET scans, economic strain and financial decision-making among persons with cognitive impairment and care partners: a mixed-methods analysis of the CARE-IDEAS study	82
ISX9 activates the Wnt/β-catenin signaling pathway and exerts neuroprotective effects in Alzheimer’s disease	77

Lower activity of cholesteryl ester transfer protein (CETP) and the risk of dementia: a Mendelian randomization analysis	76
Investigating the Aβ and tau pathology in autosomal dominant Alzheimer’s disease: insights from hybrid PET/MRI and network mapping	74
Genetic and clinical landscape of Chinese frontotemporal dementia: dominance of TBK1 and OPTN mutations	70
Association between antemortem plasma and structural MRI biomarkers and postmortem tau pathology in the Mayo Clinic Study of Aging	69
High-affinity antibodies specific to the core region of the tau protein exhibit diagnostic and therapeutic potential for Alzheimer’s disease	67
Linking oxysterols and different stages of mild cognitive impairment: insights from gut metabolites and N6-methyladenosine	66
Fluid biomarkers for neurodegenerative diseases: a comprehensive update	66
Granulovacuolar degeneration bodies are independently induced by tau and α-synuclein pathology	65
The economic burden of subjective cognitive decline, mild cognitive impairment and Alzheimer's dementia: excess costs and associated clinical and risk factors	64
Cornuside alleviates cognitive impairments induced by Aβ1−42 through attenuating NLRP3-mediated neurotoxicity by promoting mitophagy	63
Meprin-β levels are increased in the brain and the cerebrospinal fluid of Alzheimer’s disease patients	60
Impact of effective connectivity within the Papez circuit on episodic memory: moderation by perivascular space function	59
Automated high-throughput quantification of plasma p-tau217 and APOE-ε4 for Alzheimer’s disease diagnosis and cognitive decline in a memory cohort	59
Tau seeding activity in the cerebrospinal fluid of Alzheimer disease patients predicts short-term cognitive decline	58
Correction: Applicability of in vivo staging of regional amyloid burden in a cognitively normal cohort with subjective memory complaints: the INSIGHT-preAD study	57
Functional gradients of the medial parietal cortex in a healthy cohort with family history of sporadic Alzheimer’s disease	54
Mapping the long-term delayed recall-based cortex-hippocampus network constrained by the structural and functional connectome: a case-control multimodal MRI study	54
Cerebral Aβ deposition precedes reduced cerebrospinal fluid and serum Aβ42/Aβ40 ratios in the AppNL−F/NL−F knock-in mouse model of Alzheimer’s disease	53
Health-related quality of life in subjective cognitive decline and mild cognitive impairment: a longitudinal cohort analysis	53
Palmitoylation of death receptor p75NTR contributes to Alzheimer’s disease progression by regulating APP trafficking and degradation	51
Hormone therapy is associated with lower Alzheimer’s disease tau biomarkers in post-menopausal females -evidence from two independent cohorts	51
Identification of methylation-regulated genes modulating microglial phagocytosis in hyperhomocysteinemia-exacerbated Alzheimer’s disease	51
The age-specific comorbidity burden of mild cognitive impairment: a US claims database study	50
CEST imaging combined with 1H-MRS reveal the neuroprotective effects of riluzole by improving neurotransmitter imbalances in Alzheimer’s disease mice	49
Genome-wide association studies of Alzheimer’s disease and related disorders stratified by sex, onset age, and Apolipoprotein E genotype reveal novel risk loci in African Americans	49